The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer.
 
Christina Henson
Stock and Other Ownership Interests - Baxter; Fidelity MSCI Healthcare
 
Daniel Clayburgh
Research Funding - Enzychem Lifesciences (Inst); Galera Therapeutics (Inst)
 
Arielle Shebay Lee
No Relationships to Disclose
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Regeneron; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst)
 
Mahesh R. Kudrimoti
No Relationships to Disclose
 
Douglas Adkins
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Coherus Biosciences; CUE Biopharma; Eisai Europe; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Exelixis (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst); Vaccinex (Inst)
 
Steve P. Lee
Honoraria - Novocure
Travel, Accommodations, Expenses - Galera Therapeutics
 
Noah Kalman
Consulting or Advisory Role - Naveris
 
Peter John Oppelt
Speakers' Bureau - Bristol Myers Squibb; Eisai; Merck
 
Krishna A. Rao
Consulting or Advisory Role - PRA Health Sciences
Patents, Royalties, Other Intellectual Property - Applied Biologic Materials
 
Ji Sun Park
No Relationships to Disclose
 
Sookyung Oh
No Relationships to Disclose
 
Koeun Kim
No Relationships to Disclose
 
Sun Young Yoon
No Relationships to Disclose
 
Ki Young Sohn
No Relationships to Disclose
 
Stephen T. Sonis
Employment - Biomodels; Primary Endpoint Solutions
Leadership - Biomodels; Immunity Health; Primary Endpoint Solutions; Primary Endpoint Solutions
Stock and Other Ownership Interests - BioInsight Diagnostics; Biomodels; Immunity Health; Inform Genomics
Consulting or Advisory Role - Biomodels (Inst); Primary Endpoint Solutions (Inst)
Research Funding - Biomodels (Inst); Primary Endpoint Solutions (Inst)
Patents, Royalties, Other Intellectual Property - Predictive genomics (Inst); Raman spectropscopy